EU/3/07/437

Table of contents

About

On 20 March 2007, orphan designation (EU/3/07/437) was granted by the European Commission to Santhera Pharmaceuticals (Deutschland) GmbH, Germany, for idebenone for the treatment of Duchenne muscular dystrophy.

The name of the sponsor changed to Santhera Pharmaceuticals (Deutschland) GmbH in September 2010.

Key facts

Active substance
idebenone
Disease / condition
Treatment of Duchenne muscular dystrophy
Date of decision
20/03/2007
Outcome
Positive
Orphan decision number
EU/3/07/437

Sponsor's contact details

Santhera Pharmaceuticals (Deutschland) GmbH
Marie-Curie Strasse 8
D-79539 Lörrach
Germany
Tel. +49 7621 1690200
Fax +49 7621 1690201
E-mail: office@santhera.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating